TCT 398: Endovascular Ultrasound Renal Denervation to Treat Uncontrolled Hypertension: Six-Month Results Following Blinded Medication Titration in the Randomized, Sham-Controlled RADIANCE II Pivotal Trial
We Recommend
Disclosures
Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:
- Grant Support/Research Contract - Recor Medical; Novartis; idorsia
- Consultant Fee/Honoraria/Speaker's Bureau - Medtronic; AstraZenca; Novartis; Alnylam; idorsia